Literature DB >> 2421761

Fibroblast radiosensitivity and intraocular fibrovascular proliferation following radiotherapy for bilateral retinoblastoma.

D M Albert, D S Walton, R R Weichselbaum, J R Cassady, J B Little, D Leombruno, R Trantravahi, C A Puliafito.   

Abstract

A 5-day-old female patient was found to have large hereditary retinoblastomas in the posterior pole of each eye. The patient received radiation treatment over a 39-day period, with each retina receiving 4600 rad. Two weeks after the complete treatment the tumours had regressed to approximately one-quarter of their original size. By 14 weeks following completion of radiotherapy the patient had developed in each eye extensive iris neovascularisation with progressive closure of the filtration angles, secondary glaucoma, and retinal detachments resulting from fibrovascular proliferation on the retinal surface. Radiosensitivity studies were from separate conjunctival biopsies obtained before and after radiation. These showed a D0 (calculated survival curve parameters, defined in the Methods section) in the exponential growth phase of 110 prior to radiation and a postirradiation exponential growth phase D0 of 70. Karotype studies showed several chromosomal abnormalities following radiotherapy. The clinical course and pathology findings are thought to represent an unusually severe orbital and ocular response to radiation therapy. These findings are consistent with our hypothesis that some patients with hereditary retinoblastoma may have a defect in the accumulation repair of x-irradiation induced DNA damage.

Entities:  

Mesh:

Year:  1986        PMID: 2421761      PMCID: PMC1041012          DOI: 10.1136/bjo.70.5.336

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  Ocular effects of high intensity gamma radiation in the cat.

Authors:  F C WINTER; P R REINHARDT; J MADDEN
Journal:  Am J Ophthalmol       Date:  1958-07       Impact factor: 5.258

2.  Skin fibroblasts from a D-deletion type retinoblastoma patient are abnormally X-ray sensitive.

Authors:  R R Weichselbaum; J Nove; J B Little
Journal:  Nature       Date:  1977-04-21       Impact factor: 49.962

3.  Retinoblastoma and iris neovascularization.

Authors:  D S Walton; W M Grant
Journal:  Am J Ophthalmol       Date:  1968-04       Impact factor: 5.258

4.  Radiation induced neoplasia following external beam therapy for children with retinoblastoma.

Authors:  R H Sagerman; J R Cassady; P Tretter; R M Ellsworth
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1969-03

5.  Visual results and ocular complications following radiotherapy for retinoblastoma.

Authors:  P R Egbert; S S Donaldson; K Moazed; A R Rosenthal
Journal:  Arch Ophthalmol       Date:  1978-10

6.  The gorilla karyotype: chromosome lengths and polymorphisms.

Authors:  D A Miller; I L Firschein; V G Dev; R Tantravahi; O J Miller
Journal:  Cytogenet Cell Genet       Date:  1974

7.  Retinal and optic nerve complications in a high dose irradiation technique of ethmoid sinus and nasal cavity.

Authors:  L J Shukovsky; G H Fletcher
Journal:  Radiology       Date:  1972-09       Impact factor: 11.105

8.  X-ray sensitivity of fifty-three human diploid fibroblast cell strains from patients with characterized genetic disorders.

Authors:  R R Weichselbaum; J Nove; J B Little
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

9.  Rubeosis iridis in retinoblastoma and pseudoglioma.

Authors:  G Spaulding
Journal:  Trans Am Ophthalmol Soc       Date:  1978

10.  X-ray sensitivity of diploid fibroblasts from patients with hereditary or sporadic retinoblastoma.

Authors:  R R Weichselbaum; J Nove; J B Little
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

View more
  1 in total

1.  Proliferative Vitreoretinopathy in Treated Retinoblastoma.

Authors:  Cindy S Hwang; Pia R Mendoza; Jill R Wells; Hans E Grossniklaus; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2017 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.